pdatanews282
event5 outcomes

Will the FDA approve intismeran autogene (V940/mRNA-4157)?

Kalshi·Science and Technology·ends Jul 8, 2028

As of 22:13 UTC on 21 Oct 2026, the highest-priced of the 5 markets in “Will the FDA approve intismeran autogene (V940/mRNA-4157)?” on Kalshi are “Before Jan 1, 2028” at 73%, “Before Oct 1, 2027” at 69% and “Before Jul 1, 2027” at 9%. The event has no Kalshi-reported volume in the last 24 hours. pdata.world compares it with 24 related events on Kalshi, Polymarket and Manifold.

vol cum
$2.1k
vol 24h
$0
outcomes
5
ends
Jul 8, 2028
outcomesclick to inspect →
marketselected outcome
Before Jan 1, 2028
rank #1
United States
73¢
vol cum
$1.2k
vol 24h
$0
spread
0.09
ends
Jan 8, 2028

If the FDA approves intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma for marketing before Jan 1, 2028, then the market resolves to Yes.

timeline
opened · Aug 19, 2026opencloses · Jan 8, 2028
Before Jan 1, 2028 · prices over time
−24h
now
no price history yet
volume · by outcomehover a column to inspect
no volume history

similar markets

suggested by pdata